Notch signaling is a cell-to-cell communication system that controls how cells develop, what they become, and whether they multiply or die. It works through direct physical contact between neighboring cells, making it fundamentally different from pathways that rely on hormones or other signals traveling through the bloodstream. Found in nearly all animals, from fruit flies to humans, it is one of the most ancient and conserved signaling systems in biology.
How the Pathway Works
Notch signaling requires two neighboring cells to physically touch. One cell displays a signaling protein (a ligand) on its surface, and the adjacent cell carries a Notch receptor. When the ligand locks onto the receptor, it triggers a chain of molecular cuts that ultimately sends a message into the nucleus of the receiving cell.
The process unfolds in three cleavage steps, each performed by a different enzyme. The first cut (called S1) happens before signaling even begins: during the receptor’s normal maturation inside the cell, a furin-like enzyme trims it into two pieces that stay loosely connected and travel together to the cell surface. This primes the receptor for action.
The second cut (S2) is the critical activation step. When a ligand on a neighboring cell grabs the receptor, it exerts a mechanical pulling force that physically changes the receptor’s shape, exposing a hidden site. A metalloprotease enzyme then clips the receptor at that exposed site, releasing the outer portion. What remains is a short stub still embedded in the cell membrane.
The third and final cut (S3) is performed by an enzyme complex called gamma-secretase, which slices through the membrane-bound stub and frees the inner portion of the receptor. This freed fragment, known as the Notch intracellular domain, then travels straight into the nucleus with no middlemen. Once inside, it teams up with two other proteins, CSL (a DNA-binding protein) and MAML (a coactivator), forming a three-protein complex that sits on specific genes and switches them on. Without that intracellular fragment arriving in the nucleus, those target genes stay silent.
Receptors and Ligands in Humans
Humans have four Notch receptors: Notch-1, Notch-2, Notch-3, and Notch-4. Each is a large protein that spans the cell membrane, with a long extracellular arm that detects signals and an intracellular tail that carries the message inside.
On the signaling side, five ligands can activate these receptors: three Delta-like proteins (DLL-1, DLL-3, and DLL-4) and two Jagged proteins (Jagged 1 and Jagged 2). Different combinations of receptors and ligands are active in different tissues, which is one reason Notch signaling can produce such varied outcomes depending on context. A Notch signal in a developing blood cell does something entirely different from a Notch signal in the intestinal lining, even though the core machinery is the same.
Lateral Inhibition: How Cells Choose Their Fate
One of the most important things Notch does is help groups of identical cells sort themselves into different types. The best-studied version of this is called lateral inhibition, first described in fruit flies during brain development.
Imagine a sheet of identical precursor cells, all capable of becoming nerve cells. Each cell carries both Notch receptors and ligands. Small random differences in how much ligand each cell produces get amplified through feedback loops: a cell that produces slightly more ligand signals its neighbors more strongly, activating their Notch receptors. Activated Notch, in turn, suppresses the neighbor’s ability to produce ligand. Meanwhile, the high-ligand cell suppresses its own Notch activity internally. The result is a self-reinforcing pattern where some cells commit to becoming neurons (the signal senders) while their immediate neighbors take on a supporting role (the signal receivers). This creates the evenly spaced distribution of nerve cells seen across developing tissue.
Roles in Development and Tissue Maintenance
Beyond sorting nerve cells, Notch signaling is involved in a wide range of developmental processes. It helps regulate blood vessel formation, guides immune cell development, maintains stem cell populations in the gut and skin, and shapes the heart during embryonic growth. In the blood system, Notch signals direct precursor cells toward specific lineages, influencing whether a cell becomes a T cell, a B cell, or a myeloid cell.
In adults, the pathway remains active in tissues that constantly renew themselves. Intestinal stem cells, for example, rely on Notch signaling to balance self-renewal with the production of specialized absorptive cells. The pathway essentially acts as a traffic controller at cellular decision points throughout life.
Notch and Cancer: Oncogene or Tumor Suppressor?
Notch’s role in cancer is unusually complex because it can drive tumor growth in some tissues and suppress it in others. The direction depends on what the pathway normally does in that cell type.
In T-cell acute lymphoblastic leukemia (T-ALL), activating mutations in NOTCH1 are a hallmark of the disease. The pathway’s oncogenic potential in T-cell leukemia has been demonstrated both in lab models and in patients. Activating NOTCH1 mutations have also been identified in chronic lymphocytic leukemia, and NOTCH2 mutations appear in splenic marginal zone lymphoma. Notch hyperactivation has also been implicated in breast cancer.
In myeloid blood cancers, however, Notch plays the opposite role. Deleting Notch1 and Notch2 in blood-forming cells leads to uncontrolled myeloid cell proliferation resembling chronic myelomonocytic leukemia. In certain forms of acute myeloid leukemia, activating Notch actually triggers cancer cell death, while blocking Notch accelerates leukemic growth. The pathway acts as a clear tumor suppressor in these contexts, preventing the uncontrolled expansion of myeloid cells.
This dual nature makes therapeutic targeting tricky. Broadly shutting down Notch signaling might help in one cancer type while worsening another.
Genetic Disorders Linked to Notch
Because Notch signaling touches so many developmental processes, mutations in its components cause several inherited diseases.
CADASIL
CADASIL is a hereditary condition affecting small blood vessels in the brain, caused by mutations in the NOTCH3 gene on chromosome 19. Estimated prevalence is 1.3 to 5 per 100,000 people, though the condition is likely underdiagnosed. The six most common disease-causing mutations are all missense changes (single amino acid swaps), with one called p.R133C being the most frequently reported worldwide.
The disease typically causes recurrent strokes, progressive cognitive decline, migraines with aura, and mood disturbances. Brain MRI scans can reveal characteristic white matter changes even before symptoms appear, with increased signal in specific regions including the external capsule and anterior temporal lobes. Skin biopsies can also aid diagnosis, since abnormal protein deposits accumulate in blood vessel walls throughout the body.
Alagille Syndrome
Alagille syndrome primarily affects the liver and is caused by mutations in JAG1 (one of the Notch ligands) in most cases, with NOTCH2 mutations accounting for 1 to 2 percent of cases. The core problem is a reduced number of bile ducts in the liver, which impairs bile flow. This leads to severe skin itchiness, jaundice, dark urine, pale stools, and fatty deposits under the skin. Children with the condition often show poor growth and low energy.
The syndrome also affects development beyond the liver. Heart defects and murmurs are common. Doctors may notice distinctive facial features (wide forehead, pointed chin and nose), butterfly-shaped vertebrae on X-rays, and white or gray-white rings on the surface of the eye that do not affect vision. Blood vessel narrowing, particularly in the head and neck, and kidney problems can also occur.
Therapeutic Targeting
The most explored approach to blocking Notch signaling in cancer has been gamma-secretase inhibitors, drugs that prevent the third cleavage step and stop the intracellular signal from being released. These compounds were originally developed for Alzheimer’s disease, since gamma-secretase also processes a protein involved in amyloid plaque formation. Researchers later repurposed them as potential anticancer agents.
Results in clinical trials have been mixed. In most solid tumors, gamma-secretase inhibitors have failed to show meaningful benefit. Trials in ovarian cancer, melanoma, and pancreatic cancer all showed median progression-free survival of roughly 1.3 to 1.5 months, essentially no improvement.
The standout exception is desmoid tumors, a rare type of soft tissue growth. In early trials of one gamma-secretase inhibitor (later named nirogacestat), five of seven evaluable desmoid tumor patients achieved partial responses, with benefits lasting nearly 4 to 6 years. A follow-up phase II trial confirmed these results: 29 percent of patients had partial responses and the rest had stable disease, with no cases of progression. These results led to a phase III trial and breakthrough therapy designation from the U.S. Food and Drug Administration. Some central nervous system tumors have also shown modest responses.
The challenge with gamma-secretase inhibitors is that they block Notch signaling everywhere, not just in tumors. Since Notch is essential for maintaining the intestinal lining, gut toxicity has been a persistent side effect in clinical trials. More targeted approaches, such as antibodies against specific Notch receptors or ligands, are being explored to reduce these off-target effects while preserving anticancer activity.